Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease. WHY IT'S IMPORTANT ...

Novo Nordisk will start selling its obesity drug Wegovy directly to patients at a reduced price, following a similar move ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

Fact checked by Nick Blackmer Novo Nordisk launched a direct-to-consumer program last week to sell Wegovy at a reduced price ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...

Patients who received preoperative semaglutide (Ozempic, Wegovy) for 24.4 weeks lost a ... Semaglutide wasn't approved for obesity at higher doses until 2021, and therefore maximum weight-loss ...

Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the ...

The weight-loss drug can cost patients more than $1,000 a month if they do not have health insurance coverage.

on Friday, March 1, 2024. (AP Photo/Amanda Andrade-Rhoades, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day ...

A gene linked to obesity in Labradors is the same one found in humans, scientists say. The discovery could help researchers ...